IDEXX Laboratories, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from IDEXX Laboratories, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 7.5 times. Higher than 93% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$108Over the last 3 years, every $100 of reported profit came with $108 of operating cash.
Lower than 81% of Healthcare companies in United States.
Self-Funding Ratio
7.5×Over the last 3 years its own operating cash covered its investment spending (capex) 7.5 times.
Higher than 93% of Healthcare companies in United States.
Cash Locked Ratio
$20For every $100 of sales, $20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $21 tied up three years earlier.
Less money tied up than 57% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$41Sales grew 28% in 3 years; of every extra $100 of sales, $41 became extra profit.
Higher than 65% of Healthcare companies in United States.
Asset Productivity Ratio
+28% / +22%In 3 years sales changed by +28% while total assets changed by +22%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
2.5×Debt due within a year is covered 2.5 times by its yearly operating cash.
Higher than 75% of Healthcare companies in United States.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 70% of Healthcare companies in United States.
Tangible Assets Ratio
84%Of every $100 the company owns, $84 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 55% of Healthcare companies in United States.
Tangible Net Worth Ratio
67%Of every $100 of net worth, $67 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 54% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
IDEXX Laboratories, Inc. owes $0.53 for every $1 it owns. Net profit rose 19% in the year to Dec 2025, and grew 16% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
39.8Investors pay $39.8 for every $1 of IDEXX Laboratories, Inc.'s yearly profit, higher than 72% of Healthcare companies in United States.
P/B ratio
27.69The share price is 27.69 times IDEXX Laboratories, Inc.'s book value per share, higher than 96% of Healthcare companies in United States.
Market cap
$44.6 BThe total market value of all of IDEXX Laboratories, Inc.'s shares at today's price (share price × number of shares), larger than 96% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$1.6 BWhat IDEXX Laboratories, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$20.47Net worth divided by the number of shares. The share price of $566.76 is 27.7 times this, which is the P/B above.
Return on equity (ROE)
74.2%IDEXX Laboratories, Inc. earned 74.2% on its shareholders' money over the last year, higher than 98% of Healthcare companies in United States.
Owes vs Owns
0.53×IDEXX Laboratories, Inc. owes $0.53 for every $1 it owns (moderate), higher than 59% of Healthcare companies in United States.
Dividend yield
NoneIDEXX Laboratories, Inc. does not currently pay a dividend.
Revenue growth
+10%Revenue rose 10% in the year to Dec 2025, and grew 9% a year on average over 3 years.
Profit growth
+19%Net profit rose 19% in the year to Dec 2025, and grew 16% a year on average over 3 years.
Profit margin
24.6%IDEXX Laboratories, Inc. keeps $25 of every $100 of revenue as net profit.
Cash quality
1.1×Cash from IDEXX Laboratories, Inc.'s business was 1.1× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
35.0×IDEXX Laboratories, Inc.'s operating profit covered its interest costs 35.0 times in the year to Dec 2025.
Cash vs debt
Net debtIDEXX Laboratories, Inc. had $796 M more debt than cash (net debt) at Dec 2025.
Questions
What is IDEXX Laboratories, Inc.'s P/E ratio?
Investors pay $39.8 for every $1 of IDEXX Laboratories, Inc.'s yearly profit, higher than 72% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For IDEXX Laboratories, Inc.: $44.6 B ÷ $1.6 B (30 Jun 2026) = 27.7.
What is IDEXX Laboratories, Inc.'s return on equity?
IDEXX Laboratories, Inc. earned 74.2% on its shareholders' money over the last year, higher than 98% of Healthcare companies in United States.
How much does IDEXX Laboratories, Inc. owe compared with what it owns?
IDEXX Laboratories, Inc. owes $0.53 for every $1 it owns (moderate), higher than 59% of Healthcare companies in United States.
Does IDEXX Laboratories, Inc. pay a dividend?
No. IDEXX Laboratories, Inc. does not currently pay a dividend.
Is IDEXX Laboratories, Inc.'s revenue growing?
Revenue rose 10% in the year to Dec 2025, and grew 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.